secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0001558370-24-009140
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics grants performance-based stock options to NEOs vesting on FDA approval of uproleselan
--------------------------------------------------------------------------------

- CEO Harout Semerjian granted 521,250 shares; CFO Brian Hahn and CMO Edwin Rock each granted 187,500 shares.
- Options have exercise price of $0.2589 per share and vest upon FDA approval of uproleselan for AML.
- Awards are in addition to service-based options granted Jan 12, 2024 with exercise price of $3.11 per share.
- Vesting is contingent on continued service through the FDA approval date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000155837024009140/0001558370-24-009140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000155837024009140/glyc-20240610x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-009140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer